Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
440.00    -9.20 (-2.05%)
Bid:
441.60
Ask:
441.90
Spread: 0.30 (0.068%)
Market Cap: £11.07b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Q1 Trading Update

20 Apr 2023 07:00

RNS Number : 8256W
Rentokil Initial PLC
20 April 2023
Β 

20 April 2023

Β 

RENTOKIL INITIAL PLC

FIRST QUARTER TRADING UPDATE

STRONG MOMENTUM CONTINUED WITH ORGANIC GROWTH OF 6.7%

Β 

Β 

AER1

CER

Β 

Q1 2023

Β£m

Q1 2022

Β£m

Change

%

Q1 2023

Β£m

Q1 2022

Β£m

Change

%

Β 

Revenue

Β 

Β 

1,259

Β 

722

Β 

74.4%

Β 

1,240

Β 

754

Β 

64.5%

Β 

Β 

Trading in the year has started well, with reported Revenue up 64.5%, reflecting the benefit of M&A, including Terminix, and strong Organic Revenue2 growth of 6.7%. Including revenue from COVID disinfection business, Group organic growth was 5.9%. The performance has been underpinned by resilient demand and effective pricing, which has continued to offset inflationary pressures.

Β 

Regional Overview

Β 

North America delivered a good performance, with Organic Revenue growth of 4.9%. Strong momentum was sustained in Europe inc. LATAM, the Group's second largest region (+12.0% Organic Revenue), Asia & MENAT (+10.8% Organic Revenue) and Pacific (+7.5% Organic Revenue). Even with the anticipated reduction in COVID related medical waste services, the UK & Sub Saharan Africa region recorded 4.4% Organic Revenue growth.

Β 

Category Overview

Β 

Our Pest Control business delivered Organic Revenue growth of 6.4%. North America Pest Control recorded 4.9% Organic Revenue growth, driven by a strong start to the year of c.6.0% in pest control services for our commercial, residential, and termite customers. This growth was partially offset by the products distribution business, which has seen a slower start to the season contributed to by de-stocking across a number of major accounts and adverse weather conditions across some of our regional markets.

Β 

Our Hygiene & Wellbeing business, supported by continued good demand for washroom services, also performed well during the first quarter, with Organic Revenue up 5.5% (Revenue +6.2%). France Workwear continued its strong growth rates with Organic Revenue up by 17.3% (Revenue +17.3%) over the period.

Β 

M&A

Β 

Delivery of the Terminix integration plan has progressed well in the first quarter of the year and the cost synergy programme is on track to meet full year guidance.

Β 

The Group completed 15 additional bolt-on acquisitions in the first quarter - 12 in Pest Control and 3 in Hygiene & Wellbeing, with combined annualised revenues in the year prior to acquisition of c.Β£63m. This included the acquisition of RK Environmental/Comprehensive Food Safety, a specialist in pest management services and food safety audit consulting to the commercial food industry operating in 31 US states. RK had annualised revenues of c.$22m in the year prior to purchase, ranking #44 on the Pest Control Technology 2022 Top 100 list. We have built a substantial pipeline of high-quality opportunities and remain confident in our targeted spend of c.Β£250m in 2023.

Β 

In March 2023, Rentokil Initial was named as one of Britain's Most Admired Companies3 for the quality of its products and services.

Β 

Commenting on today's trading update, Andy Ransom, Chief Executive, said:

Β 

"I am delighted with the performance our colleagues delivered in Q1, which demonstrates the resilience of our compounding growth model and continued strategy execution. This performance, combined with further progress in our value-creating M&A programme led by the integration of Terminix, means we are well positioned for the remainder of the year. We reiterate our 2023 full year expectations."

Β 

Β 

Summary of financial performance (at CER)

Β 

Regional Performance

Β 

Β 

Β 

Β 

Β 

Β 

Revenue

Organic Revenue growth excluding disinfection

Organic Revenue growth including disinfection

Q1 2023 Β£m

Q1 2022 Β£m

Β 

Change

%

Q1

2023

%

Q1

2023

%

Β 

Β 

Β 

Β 

Β 

North America

745

320

132.9%

4.9%

4.8%

Pest Control

723

298

142.6%

4.9%

4.9%

Hygiene & Wellbeing

22

22

1.0%

4.2%

1.0%

Β 

Β 

Β 

Β 

Β 

Europe (inc LATAM)

254

211

20.4%

12.0%

10.5%

Pest Control

120

90

34.2%

11.2%

11.2%

Hygiene & Wellbeing

82

77

6.2%

9.9%

5.9%

France Workwear

52

44

17.3%

17.3%

17.3%

Β 

Β 

Β 

Β 

Β 

UK & Sub Saharan Africa

94

90

4.5%

4.4%

4.3%

Pest Control

50

45

11.0%

10.5%

10.5%

Hygiene & Wellbeing

44

45

(1.8%)

(1.7%)

(1.8%)

Β 

Β 

Β 

Β 

Β 

Asia & MENAT

84

77

9.5%

10.8%

4.2%

Pest Control

62

53

16.8%

11.1%

11.1%

Hygiene & Wellbeing

22

24

(7.0%)

9.5%

(11.6%)

Β 

Β 

Β 

Β 

Β 

Pacific

61

54

11.9%

7.5%

7.5%

Pest Control

29

24

21.7%

12.5%

12.5%

Hygiene & Wellbeing

32

30

4.1%

3.6%

3.5%

Β 

Β 

Β 

Β 

Β 

Central

2

2

4.7%

-

-

Total at CER

1,240

754

64.5%

6.7%

5.9%

Total at AER

1,259

722

74.4%

Β 

Β 

Β 

Β 

Β 

Category Performance

Β 

Β 

Β 

Β 

Β 

Revenue

Organic Revenue growth excluding disinfection

Organic Revenue growth including disinfection

Q1 2023 Β£m

Q1 2022 Β£m

Β 

Change

%

Q1

2023

%

Q1

2023

%

Β 

Β 

Β 

Β 

Β 

Pest Control

984

510

93.2%

6.4%

6.4%

Hygiene & Wellbeing

202

198

1.9%

5.5%

1.1%

France Workwear

52

44

17.3%

17.3%

17.3%

Central

2

2

4.7%

-

-

Total at CER

1,240

754

64.5%

6.7%

5.9%

Total at AER

1,259

722

74.4%

Β 

Β 

Β 

Β 

Β 

Enquiries:

Β 

Investors / Analysts: Peter Russell, Rentokil Initial plc, + 44 7795 166506

Media: Malcolm Padley, Rentokil Initial plc, +44 7788 978199

Β 

Β 

Notes

Β 

1AER - actual exchange rates; CER - constant 2022 exchange rates

Β 

2Organic Revenue growth represents the growth in Revenue excluding the effect of businesses acquired during the year and, unless stated otherwise, exclude COVID disinfection. Acquired businesses are included in organic measures in the year following acquisition, and the comparative period is adjusted to include an estimated full year performance for growth calculations (pro forma revenue). The Terminix acquisition is treated differently to other acquisitions for Organic Revenue growth purposes. The full pre-acquisition results of the Terminix business are included for the comparative period and Organic Revenue growth is calculated as the growth in Revenue compared to the comparative period.

Β 

3Britain's Most Admired CompaniesΒ measures the reputation of more than 250 of Britain's largest companies across 28 industry sectors and it has been running since 1990. The survey is run by Echo Research with the support from academic partners, Coventry University.

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTMZGMDRLGGFZM
Date   Source Headline
11th Jan 20084:08 pmRNSHolding(s) in Company
10th Jan 200810:19 amRNSHolding(s) in Company
27th Dec 200710:11 amRNSDisposal
21st Dec 20079:57 amRNSHolding(s) in Company
20th Dec 200712:18 pmRNSDirector/PDMR Shareholding
18th Dec 20074:37 pmRNSDirector/PDMR Shareholding
14th Dec 20074:48 pmRNSHolding(s) in Company
14th Dec 200712:39 pmRNSDirector/PDMR Shareholding
13th Dec 20074:19 pmRNSDirector/PDMR Shareholding
13th Dec 20077:01 amRNSTrading Statement
12th Dec 200710:28 amRNSHolding(s) in Company
8th Nov 20077:01 amRNS3rd Quarter Results
19th Oct 200712:27 pmRNSAnnual Calendar 2008
17th Oct 20072:47 pmRNSHolding(s) in Company
8th Oct 20074:16 pmRNSDirector/PDMR Shareholding
1st Oct 20074:20 pmRNSTotal Voting Rights
28th Sep 20074:43 pmRNSDirector/PDMR Shareholding
25th Sep 200710:09 amRNSHolding(s) in Company
23rd Aug 20077:00 amRNSInterim Results
8th Aug 20072:57 pmRNSHolding(s) in Company
31st Jul 20079:50 amRNSTotal Voting Rights
30th Jul 200710:55 amRNSHolding(s) in Company
30th Jul 20077:01 amRNSAcquisition
19th Jul 20077:00 amRNSDirectorate Change
17th Jul 20077:00 amRNSAcquisition
9th Jul 200712:38 pmRNSHolding(s) in Company
2nd Jul 20074:27 pmRNSDisposal
29th Jun 200712:04 pmRNSHolding(s) in Company
27th Jun 20074:16 pmRNSRegulatory Inquiry Outcome
21st Jun 200710:47 amRNSHolding(s) in Company
11th Jun 200710:41 amRNSHolding(s) in Company
31st May 20074:27 pmRNSTotal Voting Rights
24th May 200710:01 amRNSHolding(s) in Company
3rd May 20075:50 pmRNSAGM Statement
2nd May 20077:01 amRNSTrading Update
1st May 20073:43 pmRNSTotal Voting Rights
24th Apr 20071:21 pmRNSCorporate Responsibility Rev
20th Apr 20078:00 amRNSDoc re. Company News
20th Apr 20078:00 amRNSAcquisition
19th Apr 200711:39 amRNSAnnual Information Update
30th Mar 20072:41 pmRNSAnnual Report and Accounts
30th Mar 20077:04 amRNSDisposal
15th Mar 20077:02 amRNSRentokil Tropical Plants
13th Mar 20079:04 amRNSHolding(s) in Company
7th Mar 20074:52 pmRNSDirector/PDMR Shareholding
7th Mar 200712:25 pmRNSStatement re: OFT clearance
28th Feb 20075:00 pmRNSDirector/PDMR Shareholding
22nd Feb 20077:02 amRNSFinal Results
21st Feb 20075:09 pmRNSHolding(s) in Company
31st Jan 20075:40 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.